Yahoo Finance Independent Non-Executive Director Michael Bradfield Just Bought 6.4% More Shares In Advanced Oncotherapy plc (LON:AVO)
Even if it's not a huge purchase, we think it was good to see that Michael Bradfield, the Independent Non-Executive Director of Advanced Oncotherapy plc (LON:AVO) recently shelled out UK£66k to buy stock, at UK£0.13 per share. However, it only increased their shares held by 6.4%, and it wasn't a huge purchase by absolute value, either.
See our latest analysis for Advanced Oncotherapy
Advanced Oncotherapy Insider Transactions Over The Last Year
In fact, the recent purchase by Michael Bradfield was the biggest purchase of Advanced Oncotherapy shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of UK£0.14 per share to be enticing. That means they have been optimistic about the company in the past, though they may have changed their mind. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. In this case we're pleased to report that the insider purchases were made at close to current prices.
Advanced Oncotherapy insiders may have bought shares in the last year, but they didn't sell any. The average buy price was around UK£0.18. These transactions suggest that insiders have considered the current price attractive. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Does Advanced Oncotherapy Boast High Insider Ownership?
Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Advanced Oncotherapy insiders own about UK£15m worth of shares. That equates to 20% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
So What Does This Data Suggest About Advanced Oncotherapy Insiders?
The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. When combined with notable insider ownership, these factors suggest Advanced Oncotherapy insiders are well aligned, and that they may think the share price is too low. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 5 warning signs for Advanced Oncotherapy (of which 3 are a bit unpleasant!) you should know about.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
